Sagimet Biosciences Inc. Series A Common Stock (SGMT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Sagimet Biosciences Inc. Series A Common Stock stock (SGMT) is currently trading at $4.62. Sagimet Biosciences Inc. Series A Common Stock PS ratio (Price-to-Sales) is 52.50. Analyst consensus price target for SGMT is $25.78. WallStSmart rates SGMT as Sell.
- SGMT PE ratio analysis and historical PE chart
- SGMT PS ratio (Price-to-Sales) history and trend
- SGMT intrinsic value — DCF, Graham Number, EPV models
- SGMT stock price prediction 2025 2026 2027 2028 2029 2030
- SGMT fair value vs current price
- SGMT insider transactions and insider buying
- Is SGMT undervalued or overvalued?
- Sagimet Biosciences Inc. Series A Common Stock financial analysis — revenue, earnings, cash flow
- SGMT Piotroski F-Score and Altman Z-Score
- SGMT analyst price target and Smart Rating
Sagimet Biosciences Inc. Series A
📊 No data available
Try selecting a different time range
Smart Analysis
Sagimet Biosciences Inc. Series A Common Stock (SGMT) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Sagimet Biosciences Inc. Series A Common Stock (SGMT) Key Strengths (1)
Trading at 1.41x book value, attractively priced
Supporting Valuation Data
Sagimet Biosciences Inc. Series A Common Stock (SGMT) Areas to Watch (4)
Company is destroying shareholder value
Very expensive at 52.5x annual revenue
Micro-cap company with very limited liquidity and high volatility
Moderate institutional interest at 45.02%
Supporting Valuation Data
Sagimet Biosciences Inc. Series A Common Stock (SGMT) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 1 register as strengths (avg 8.0/10) while 4 fall into concern territory (avg 2.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (1.41) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Market Cap. Some valuation metrics including Price/Sales (52.50) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -38.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -38.20% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SGMT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SGMT's Price-to-Sales ratio of 52.50x sits near its historical average of 52.5x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 52.5x set in Feb 2026, and 0% above its historical low of 52.5x in Feb 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Sagimet Biosciences Inc. Series A Common Stock (SGMT) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Sagimet Biosciences Inc. Series A Common Stock operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Debt-to-equity ratio of 0.00 indicates a conservative balance sheet with 32M in cash.
Free cash flow is -12M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 3.40, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Sagimet Biosciences Inc. Series A Common Stock.
Bottom Line
Sagimet Biosciences Inc. Series A Common Stock offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Sagimet Biosciences Inc. Series A Common Stock(SGMT)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Sagimet Biosciences Inc. (SGMT) is a cutting-edge biotechnology firm specializing in the development of innovative therapies for metabolic diseases, particularly non-alcoholic steatohepatitis (NASH). The company is actively advancing its lead therapeutic candidate through clinical trials, leveraging novel mechanisms aimed at significantly improving patient outcomes. With a seasoned leadership team and a comprehensive intellectual property portfolio, Sagimet is well-positioned to take advantage of the growing demand for effective treatments in the metabolic disease arena, presenting a promising opportunity for institutional investors looking to engage with the evolving biotech market.